Small Intestinal Bacterial Overgrowth Complicating Gastrointestinal Manifestations of Systemic Sclerosis: A Systematic Review and Meta-Analysis

Shah, Ayesha; Pakeerathan, Veenaa; Jones, Michael P.; Kashyap, Purna C.; Virgo, Kate; Fairlie, Thomas; Morrison, Mark; Ghoshal, Uday C; Holtmann, Gerald

doi:10.2139/ssrn.4074669

Cited by 1 publication

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the glucose breath test is already recognized as a noninvasive diagnostic tool for SIBO and is extensively used in clinical settings for diagnosis and follow-up. 33,34 Our study showed that the conversion rate of GBT positivity and breath H 2 -CH 4 concentrations in the combination therapy group was not statistically different from those in the rifaximin group. However, the combination therapy numerically decreased the total concentration of breath H 2 -CH 4 and also at different time points during the GBT (Table 3 and Fig.…”

Section: Discussionmentioning

confidence: 63%

Effect of Trimebutine and Rifaximin on Breath Hydrogen and Methane by Glucose Breath Test in Patients With Functional Bloating: A Randomized Double-blind Clinical Trial

Jo,

Paik,

Lee

et al. 2024

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/Aims Drugs that stabilize intestinal motility may improve the efficacy of nonabsorbable antibiotics, such as rifaximin, against small intestinal bacterial overgrowth (SIBO). We compared the efficacy of rifaximin alone with that of its combination with trimebutine maleate against SIBO. Methods We performed a randomized double-blind placebo-controlled trial (https://cris.nih.go.kr, no. KCT0004836) that included patients with functional bloating, no constipation, and SIBO using the hydrogen (H 2 )–methane (CH 4 ) glucose breath test (GBT). Patients were randomized into 2 groups in a 1:1 ratio, namely rifaximin (1200 mg/day) + trimebutine maleate (600 mg/day) group and rifaximin + placebo group, for 2 weeks. Patients completed a symptom questionnaire and underwent a GBT at baseline and at 1 month after treatment withdrawal. The primary outcome was SIBO eradication. The secondary outcomes included changes in the concentrations of exhaled gases, symptoms, and presence of adverse events. Results The complete eradication rate of SIBO was 35.9% (14/39) in the rifaximin group, and 34.1% (14/41) in the combined group with no significant differences. In both groups, no significant differences were observed in GBT profiles before and after the treatment, respectively. However total breath H 2 and CH 4 concentration were conspicuously decreased in the combined group after treatment. The combined group exhibited substantial relief of bloating. The adverse events were similar in the 2 groups. Conclusion While the combination therapy was not superior over rifaximin alone for SIBO eradication, it improves the symptom of bloating with numerically reducing the concentration of breath H 2 /CH 4 .

show abstract

Section: Discussionmentioning

confidence: 63%